Eradicating Drug-tolerant Persister Cells in <i>EGFR-</i> Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
We provide a rationale for targeting TROP2 in EGFR-mutated NSCLC DTPs. In contrast to TROP2 ADC therapy, targeting of TROP2 with CAR-T cells can eliminate osimertinib-induced DTPs in vivo, revealing the promise of developing novel TROP2-based CAR-T cells to promote durable response and prevent disease relapse in patients.
Authors
- Michael Yevgeniy Tolstorukov (ORCID: https://orcid.org/0000-0002-9134-8808)
- William W. Feng (ORCID: https://orcid.org/0000-0002-8976-5020)
- Zhaorong Li (ORCID: https://orcid.org/0000-0002-5268-6986)
- Francesco Facchinetti (ORCID: https://orcid.org/0000-0001-6313-6341)
- Ludovic Fournel (ORCID: https://orcid.org/0000-0003-4530-9039)
- Audrey Mansuet‐Lupo (ORCID: https://orcid.org/0000-0002-7196-2114)
- Kenneth Ngo (ORCID: https://orcid.org/0000-0001-5511-2825)
- Sachiv Chakravarti (ORCID: https://orcid.org/0009-0006-9390-9169)
- Elliott J. Brea (ORCID: https://orcid.org/0000-0002-6283-0267)
- Pasi Antero Janne (ORCID: https://orcid.org/0000-0002-7821-4928)
- Letizia Gnetti (ORCID: https://orcid.org/0000-0002-6982-5188)
- Aisha Saldanha (ORCID: https://orcid.org/0009-0009-6757-1792)
- Marco Alifano
- Cloud Peter Paweletz (ORCID: https://orcid.org/0000-0002-2287-5663)
- David Allen Barbie (ORCID: https://orcid.org/0000-0002-5422-4275)
- Matthew Aaron Booker (ORCID: https://orcid.org/0000-0002-6902-1032)
- Nicoletta Campanini (ORCID: https://orcid.org/0009-0006-7259-5869)
- Alessandro Leonetti (ORCID: https://orcid.org/0000-0001-5415-6703)
- Simona D’Agnelli (ORCID: https://orcid.org/0000-0001-5396-9542)
- Lauren M. Zasadil (ORCID: https://orcid.org/0000-0002-2243-1667)
- Elena V. Ivanova (ORCID: https://orcid.org/0000-0002-5069-4974)
- Patrick H. Lizotte (ORCID: https://orcid.org/0000-0001-9510-0036)
- Simon Baldacci (ORCID: https://orcid.org/0000-0003-3610-1316)
- Lecia V. Sequist (ORCID: https://orcid.org/0000-0002-8965-6991)
- Filippo Lococo (ORCID: https://orcid.org/0009-0002-2462-1613)
- Karen Bui (ORCID: https://orcid.org/0000-0001-7582-853X)
- Prafulla C. Gokhale (ORCID: https://orcid.org/0000-0002-1974-5921)
- Antja-Voy Hartley (ORCID: https://orcid.org/0000-0002-5934-5885)
- Navin R. Mahadevan (ORCID: https://orcid.org/0000-0002-6805-8861)
- Marie-Anaïs Locquet (ORCID: https://orcid.org/0009-0000-2417-9912)
- Eric L. Smith (ORCID: https://orcid.org/0000-0002-0296-7587)
- Soumya Malhotra (ORCID: https://orcid.org/0009-0009-0442-4509)
- Magdalena Zielinska (ORCID: https://orcid.org/0009-0009-5366-2538)
- Bishma Tuladhar (ORCID: https://orcid.org/0000-0003-2656-5117)
- Jon A. Tsai (ORCID: https://orcid.org/0009-0006-3367-8426)
- Conor Hinchey (ORCID: https://orcid.org/0009-0005-1119-8782)
- William Haller (ORCID: https://orcid.org/0009-0000-6591-8400)
Institutions
- Università Cattolica del Sacro Cuore (IT)
- University of Parma (IT)
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Université Paris Cité (FR)
- University of Michigan (US)
- Agostino Gemelli University Polyclinic (IT)
- Massachusetts General Hospital (US)
- Sorbonne Paris Cité (FR)
- Hôpital Cochin (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Parker Institute for Cancer Immunotherapy (US)
- Michigan United (US)
- Dana-Farber Cancer Institute (US)
- Center for Cancer Research (US)
Publication Details
- Journal
- Cancer Discovery
- Published
- 2025-08-05
- DOI
- https://doi.org/10.1158/2159-8290.cd-24-1515
- Citations
- 9
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 9.41